Research programme: endostatin analogues - Bolder BioTechnologyAlternative Names: Endostatin - Bolder Biotechnology
Latest Information Update: 01 Aug 2007
At a glance
- Originator Bolder BioTechnology
- Class Angiostatic proteins
- Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 01 Aug 2007 Preclinical development is ongoing
- 03 Sep 2004 Preclinical trials in Cancer in USA (unspecified route)